This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Munger, M. A. Articles by Jarvis, R. C. Search for Related Content Social Bookmarking                         What's this?

Endocrinologic Warfare: The Role of Angiotensin-Converting Enzyme Inhibitors in Congestive Heart Failure

Division of Cardiology, University Hospitals of Cleveland, 2074 Abington Rd, Cleveland, OH 44106

Stephanie F. Gardner

Division of Cardiology, University Hospitals of Cleveland, 2074 Abington Rd, Cleveland, OH 44106

Robert C. Jarvis

Division of Cardiology, University Hospitals of Cleveland, 2074 Abington Rd, Cleveland, OH 44106

The angiotensin-converting enzyme (ACE) inhibitors represent the gold standard of vasodilator therapy for congestive heart failure through blunting of the endocrinologic manifestations of heart failure. The future role of these agents may be in the asymptomatic and mild stages of heart failure. ACE inhibitors have been shown to decrease morbidity and mortality with the natural history of this disease being altered. The future will bring many new ACE inhibitors to market, with the challenge for physicians and pharmacists to understand the important distinctions of each specific agent. © 1990 by W.B. Saunders Company.

Journal of Pharmacy Practice, Vol. 3, No. 5, 318-331 (1990)
DOI: 10.1177/089719009000300506


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?